Adenosine-containing compositions and methods for inhibiting adenosine deposition
A composition with adenosine, glycyrrhizic acid, and water maintains solubility and prevents precipitation, addressing skin irritation and ethanol sensitivity in adenosine-containing products.
Patent Information
- Application Number
- JP2021121685
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2021-07-26
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-09-01
AI Technical Summary
Adenosine-containing compositions with low ethanol content face challenges in maintaining solubility at low temperatures and preventing precipitation, which can lead to skin irritation and allergic reactions in sensitive individuals.
Incorporating 0.2% to 2.5% adenosine, 0.05% to 1.5% glycyrrhizic acid or its salts, and 60% or more water, with less than 20% ethanol, to create a composition that suppresses adenosine precipitation and facilitates redissolution at varying temperatures.
The composition maintains adenosine solubility at room temperature and prevents precipitation at low temperatures, reducing skin irritation and allowing application to ethanol-sensitive individuals.
Smart Images

Figure 0007592944000001 
Figure 0007592944000002 
Figure 0007592944000003
Abstract
Description
[Technical field]
[0001] The present disclosure relates to compositions containing adenosine. The present disclosure relates to methods for inhibiting the precipitation of adenosine in aqueous media. [Background technology]
[0002] Adenosine is known to promote blood circulation when applied to the skin. Adenosine is also known to have the effect of producing hair growth promoting factors in hair papilla cells. Therefore, adenosine is used in external skin preparations such as hair restorers (see, for example, Patent Document 1).
[0003] The topical composition described in Patent Document 1 contains 1.0 to 2.0% by mass of adenosine as a whole composition, 10.0 to 20.0% by mass of a moisturizer as a whole composition, the content of a sugar-based moisturizer in the moisturizer as a whole composition being 20.0 to 100% by mass of the whole moisturizer, and 35.0 to 65.0% by mass of a lower alcohol as a whole composition. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] JP 2008-247752 A Summary of the Invention [Problem to be solved by the invention]
[0005] The following analysis is provided in light of the present disclosure.
[0006] In order for the adenosine-containing composition described in Patent Document 1 to effectively act on the skin, adenosine must be dissolved in a solvent. However, adenosine has low solubility in water. Therefore, in the composition described in Patent Document 1, ethanol (commonly called "alcohol") is used in an amount of 30% by mass or more relative to the mass of the composition in order to dissolve adenosine in an aqueous solvent. However, when ethanol is applied to the skin, some people experience skin abnormalities or allergic reactions to ethanol. For such people who cannot apply ethanol to their skin, adenosine-containing products with a low ethanol content are desired. In addition, in recent years, there has been an increasing demand for alcohol-free skin topicals.
[0007] Even if the ethanol concentration in the aqueous solvent is reduced, adenosine can be dissolved in the aqueous solvent. However, simply reducing the ethanol concentration does not allow adenosine to maintain its dissolved state when the temperature temporarily becomes low (e.g., 0°C). For example, when the ethanol concentration is reduced in the composition described in Patent Document 1, even if adenosine can be dissolved once in a room temperature environment (e.g., 25°C or higher), adenosine cannot maintain its dissolved state and precipitates when the adenosine solution is subsequently temporarily placed in a low temperature environment (e.g., 0°C). Even if adenosine precipitates, there is no problem if adenosine can be re-dissolved when the environment is subsequently returned to room temperature (e.g., 25°C or higher). However, in a composition in which the ethanol concentration is simply reduced, the precipitated adenosine cannot be re-dissolved even when the environment is returned to room temperature. Therefore, when the ethanol concentration in the solvent is low, it is desired that adenosine does not precipitate even when the adenosine solution is temporarily in a low temperature state, or, even if it precipitates, adenosine can be naturally re-dissolved when the environment is returned to 25°C or higher.
[0008] For this reason, there is a need for an adenosine-containing composition that can suppress the precipitation of adenosine at low temperatures or can ensure the dissolution of adenosine at room temperature even when the ethanol content is low. In addition, there is a need for a method for suppressing the precipitation of dissolved adenosine and / or a method for facilitating re-dissolution of precipitated adenosine even in an aqueous solvent with a low ethanol content. [Means for solving the problem]
[0009] According to a first aspect of the present invention, there is provided an adenosine-containing composition comprising (A) 0.2-2.5% by mass of adenosine, (B) 0.05-1.5% by mass of at least one selected from the group consisting of glycyrrhizinic acid and its salts, and (C) 60% by mass or more of water, in which ethanol is less than 20% by mass relative to the mass of the adenosine-containing composition. The adenosine-containing composition is used in topical skin preparations that are applied to the skin (excluding the scalp). According to a second aspect of the present invention, there is provided an adenosine-containing composition comprising (A) 0.2-2.5% by mass of adenosine, (B) 0.05-1.5% by mass of at least one selected from the group consisting of glycyrrhizic acid and its salts, and at least one selected from the group consisting of salicylic acid and its salts, and (C) 60% by mass or more of water, in which ethanol is less than 20% by mass relative to the mass of the adenosine-containing composition.
[0010] The present disclosure 3 According to the present invention, there is provided an adenosine-containing composition comprising (A) 0.2% by mass to 2.5% by mass of adenosine, (B) at least one selected from the group consisting of glycyrrhizinic acid and its salts, and (C) 60% by mass or more of water. The adenosine-containing composition does not contain ethanol. The adenosine-containing composition is used in topical skin preparations that are applied to the skin (excluding the scalp). According to a fourth aspect of the present disclosure, there is provided an adenosine-containing composition comprising: (A) 0.2% by mass to 2.5% by mass of adenosine; (B) at least one selected from the group consisting of glycyrrhizic acid and its salts, and at least one selected from the group consisting of salicylic acid and its salts; and (C) 60% by mass or more of water. The adenosine-containing composition does not contain ethanol.
[0011] The present disclosure 5 According to one aspect, there is provided a method for inhibiting precipitation of adenosine, comprising the step of dissolving 0.2% to 2.5% by mass of adenosine and a first component in an aqueous solvent containing 60% by mass or more of water and less than 20% by mass of ethanol relative to the total mass of the composition. The first component is at least one selected from the group consisting of glycyrrhizinic acid and salts thereof. and at least one selected from the group consisting of salicylic acid and its salts. It is. Effect of the Invention
[0012] In the adenosine-containing composition of the present disclosure, even if the ethanol content is low, adenosine is dissolved in an aqueous solvent in an environment of 25° C. or higher. Furthermore, in the adenosine-containing composition of the present disclosure, adenosine is unlikely to precipitate even if the surrounding environment is at a low temperature, and even if adenosine precipitates at a low temperature, adenosine can be naturally dissolved by increasing the temperature of the surrounding environment.
[0013] According to the method for inhibiting precipitation of adenosine disclosed herein, adenosine can be dissolved in an aqueous solvent having a low ethanol content, and precipitation of the dissolved adenosine can be inhibited. Even if adenosine precipitates due to a decrease in the temperature of the surrounding environment, adenosine can be naturally dissolved by increasing the temperature of the surrounding environment. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] Preferred embodiments of each of the above aspects are described below.
[0015] According to a preferred embodiment of the first and second aspects, component (B) further comprises at least one selected from the group consisting of salicylic acid and salts thereof.
[0016] According to a preferred embodiment of the above first and second aspects, component (B) further comprises a plant extract.
[0017] Above No. 1 and second According to a preferred embodiment of the present invention, the plant extract is at least one selected from the group consisting of Angelica keiskei leaf / stem extract, apricot juice, ginkgo leaf extract, Satsuma mandarin peel extract, Scutellaria root extract, Panax ginseng root extract, Rosa canina fruit extract, Ononis extract, licorice root extract, Phellodendron amplexicaule bark extract, Sophora flavonoides root extract, cherry leaf extract, Hypericum perforatum flower / leaf / stem extract, Crataegus monogyna flower extract, Horse chestnut seed extract, Achillea millefolium extract, Rosa centifolia flower extract, Prunus yedoensis leaf extract, Camellia japonica seed extract, Camellia japonica flower extract, Tencha extract, Lotus germ extract, Myrtus officinalis leaf extract, Bupleurum falcatum root extract, Melilot extract, Centaurea cyanus flower extract, Lemon extract, Rosemary extract, Rosemary leaf extract, Wild thyme extract, and Sanguisorba officinalis extract.
[0018] According to a preferred embodiment of the above first and second aspects, component (B) further contains caffeine.
[0019] According to a preferred embodiment of the first and second aspects, component (B) is a component that inhibits precipitation of dissolved component (A).
[0020] Above No. 1 and second According to a preferred embodiment of the present invention, the content of component (A) is 0.1% by mass to 5% by mass based on the mass of the adenosine-containing composition.
[0021] The above 2 According to a preferred embodiment of the present invention, the content of component (B) is 1×10 based on the mass of the adenosine-containing composition. -4 It is at least % by mass.
[0022] Above No. 1 and second According to a preferred embodiment of the present invention, the content of component (C) is 60% by mass or more based on the mass of the adenosine-containing composition.
[0023] Above No. 1 and second According to a preferred embodiment of the present invention, the adenosine-containing composition further contains 5% by mass to 40% by mass of a polyhydric alcohol relative to the mass of the adenosine-containing composition.
[0024] Above No. 1 and second According to a preferred embodiment of the invention, the adenosine-containing composition is a one-phase liquid composition, in which components (A) and (B) are dissolved at atmospheric pressure and 25° C.
[0025] According to a preferred embodiment of the first aspect, the adenosine-containing composition is substantially free of ethanol.
[0026] Above No. 1 and second According to a preferred embodiment of the invention, the adenosine-containing composition is applied to a skin topical preparation that is applied to the skin.
[0027] Above No. 1 and second According to a preferred embodiment of the invention, the adenosine-containing composition is a skin topical agent for application to the scalp.
[0028] Above article 3 According to a preferred embodiment of the present invention, the aqueous solvent contains water in an amount of 60% by mass or more based on the mass of the aqueous solvent.
[0029] According to a preferred embodiment of the third aspect, the first component further comprises at least one selected from the group consisting of salicylic acid and salts thereof.
[0030] According to a preferred embodiment of the above third aspect, the first component further comprises a plant extract.
[0031] Above article 3 According to a preferred embodiment of the present invention, the plant extract is at least one selected from the group consisting of Angelica keiskei leaf / stem extract, apricot juice, ginkgo leaf extract, Satsuma mandarin peel extract, Scutellaria root extract, Panax ginseng root extract, Rosa canina fruit extract, Ononis extract, licorice root extract, Phellodendron amplexicaule bark extract, Sophora flavonoides root extract, cherry leaf extract, Hypericum perforatum flower / leaf / stem extract, Crataegus monogyna flower extract, Horse chestnut seed extract, Achillea millefolium extract, Rosa centifolia flower extract, Prunus yedoensis leaf extract, Camellia japonica seed extract, Camellia japonica flower extract, Tencha extract, Lotus germ extract, Myrtus officinalis leaf extract, Bupleurum falcatum root extract, Melilot extract, Centaurea cyanus flower extract, Lemon extract, Rosemary extract, Rosemary leaf extract, Wild thyme extract, and Sanguisorba officinalis extract.
[0032] According to a preferred embodiment of the third aspect, the first component further comprises caffeine.
[0033] According to a preferred embodiment of the third aspect, the first component is a component that inhibits precipitation of dissolved adenosine.
[0034] Above article 3 According to a preferred embodiment of the present invention, adenosine is added in an amount of 0.1% by mass to 5% by mass relative to the total mass of the composition.
[0035] Above article 3 According to a preferred embodiment of the present invention, the first component is added in an amount of 1×10 -4 Add at least % by mass.
[0036] Above article 3According to a preferred embodiment of the present invention, the method for inhibiting precipitation of adenosine further comprises the step of adding to the aqueous solvent 5% by mass to 40% by mass of a polyhydric alcohol relative to the total mass of the composition.
[0037] In the present disclosure, the term "substantial amount" refers to an amount that can produce an effective effect by adding the compound.
[0038] In the following description, POE is an abbreviation for polyoxyethylene, and POP is an abbreviation for polyoxypropylene, and the number in parentheses after POE or POP indicates the average number of moles of POE groups or POP groups added in the compound.
[0039] The adenosine-containing composition according to the first embodiment of the present disclosure will be described. The adenosine-containing composition of the present disclosure includes (A) adenosine, (B) at least one selected from the group consisting of caffeine, glycyrrhizic acid and its salts, salicylic acid and its salts, and plant extracts, and (C) water. The adenosine-containing composition is a liquid composition. The adenosine-containing composition is preferably a one-phase aqueous composition. The adenosine-containing composition may also be an emulsion containing an oily component.
[0040] [(A) Adenosine] Adenosine is preferably dissolved in the adenosine-containing composition at atmospheric pressure and 25° C. (After adenosine is precipitated in a low-temperature environment, the composition is preferably allowed to stand at 25° C. for 4 weeks or more.) Whether adenosine is dissolved or not can be determined by visual appearance observation.
[0041] The content of adenosine is preferably 0.1% by mass or more relative to the mass of the adenosine-containing composition. The content of adenosine can be 0.2% by mass or more, 0.3% by mass or more, 0.5% by mass or more, 0.8% by mass or more, 1% by mass or more, or 1.5% by mass or more relative to the mass of the adenosine-containing composition. If the content of adenosine is less than 0.1% by mass, the effective action of adenosine cannot be obtained. The content of adenosine is preferably 5% by mass or less relative to the mass of the adenosine-containing composition. The content of adenosine can be 4% by mass or less, 3.5% by mass or less, 3% by mass or less, 2.5% by mass or less, 2% by mass or less, 1.5% by mass or less, or 1% by mass or less relative to the mass of the adenosine-containing composition. If the content of adenosine exceeds 5% by mass, adenosine is likely to precipitate.
[0042] [(B) Precipitation suppressing component] The adenosine-containing composition of the present disclosure contains at least one component selected from the group consisting of caffeine, glycyrrhizic acid and its salts, salicylic acid and its salts, and plant extracts. In the present disclosure, for convenience, these components are referred to as precipitation-inhibiting components. The precipitation-inhibiting component is a component that can inhibit the precipitation of adenosine dissolved in a solvent, and can promote (promote) the re-dissolution of adenosine when the composition is returned to 25°C or higher even if adenosine is temporarily precipitated in the composition in a low-temperature environment (e.g., 0°C). In the adenosine-containing composition of the present disclosure, the precipitation-inhibiting component is dissolved in the adenosine-containing composition at atmospheric pressure and 25°C. When the precipitation-inhibiting component is not dissolved in the solvent, a component that solubilizes the precipitation-inhibiting component, such as a surfactant, can be added.
[0043] The plant extract is at least one selected from the group consisting of Angelica keiskei leaf / stem extract, apricot juice, ginkgo leaf extract, Satsuma mandarin peel extract, Scutellaria root extract, Panax ginseng root extract, Rosa canina fruit extract, Ononis extract, Licorice root extract, Phellodendron amplexicaule bark extract, Sophora flavescens root extract, Cherry leaf extract, Hypericum perforatum flower / leaf / stem extract, Crataegus monogyna flower extract, Horse chestnut seed extract, Achillea millefolium extract, Rosa centifolia flower extract, Prunus yedoensis leaf extract, Camellia seed extract, Camellia flower extract, Tencha extract, Lotus germ extract, Myrtacea leaf extract, Bupleurum falcatum root extract, Melilot extract, Cornflower flower extract, Lemon extract, Rosemary extract, Rosemary leaf extract, Wild thyme extract, and Sanguinea oleracea extract. The above plant extracts are listed by the cosmetic ingredient name. Even if a plant extract has a quasi-drug ingredient name that is different from the above cosmetic ingredient name, it may be included in the above plant extract if it has the same INCI name.
[0044] It is more preferable that the precipitation-inhibiting component includes at least one component selected from the group consisting of caffeine, glycyrrhizic acid and its salts, salicylic acid and its salts, apricot juice, ginkgo leaf extract, licorice root extract, sophora flavonoides root extract, camellia flower extract, lemon extract, wild thyme extract, and sanguisorba officinalis extract.
[0045] The above-mentioned plant extract can be a commercially available product. The plant extract can be obtained by immersing the leaves, stems including rhizomes, fruits, roots, etc. of the above-mentioned plant or the whole plant with an extraction solvent, optionally heating under reflux, filtering, and concentrating. The extraction solvent can be any solvent that is usually used for extraction, and in particular, organic solvents such as alcohols such as methanol and ethanol, water-containing alcohols, acetone, and ethyl acetate can be used alone or in combination, or extraction can be performed with water.
[0046] The content of the precipitation inhibitor is 1×10 -4The content of the precipitation-inhibiting component is preferably 2×10% by mass or more based on the mass of the adenosine-containing composition. -4 Mass% or more, 5×10 -4 Mass% or more, 8×10 -4 Mass% or more, 1×10 -3 Mass% or more, 2×10 -3 Mass% or more, 3×10 -3 Mass% or more, 5×10 -3 Mass% or more, 8×10 -3 The content of the precipitation-inhibiting component may be 1×10 mass% or more, 0.01 mass% or more, 0.02 mass% or more, 0.05 mass% or more, or 0.07 mass% or more. -4 If the content is less than 1.5% by mass, the effect of inhibiting adenosine precipitation cannot be obtained. The precipitation-inhibiting component can be added up to the solubility. The content of the precipitation-inhibiting component is, for example, 1.5% by mass or less, 1% by mass or less, 0.8% by mass or less, 0.5% by mass or less, 0.2% by mass or less, 0.1% by mass or less, 0.05% by mass or less, 0.02% by mass or less, 0.01% by mass or less, or 5×10 -3 It can be 50% by mass or less.
[0047] For example, caffeine, glycyrrhizic acid and its salts, and salicylic acid and its salts can each be 0.01% by mass or more, preferably 0.05% by mass or more, based on the mass of the adenosine-containing composition. -4 % by mass or more, preferably 1×10 -3 % by mass or more, more preferably 2×10 -3 The content of the plant extract is based on the pure content.
[0048] The amount of the deposition-inhibiting component is preferably 0.001 parts by mass or more relative to 1 part by mass of adenosine. The amount of the deposition-inhibiting component can be 0.002 parts by mass or more, 0.005 parts by mass or more, 0.008 parts by mass or more, 0.01 parts by mass or more, 0.05 parts by mass or more, or 0.1 parts by mass or more relative to 1 part by mass of adenosine. If the amount of the deposition-inhibiting component is less than 0.001 parts by mass, the deposition-inhibiting effect is reduced. The amount of the deposition-inhibiting component can be 1 part by mass or less relative to 1 part by mass of adenosine.
[0049] [(C)Water] As the water, water used in cosmetics, quasi-drugs, etc. can be used, for example, purified water, ion-exchanged water, tap water, etc.
[0050] The water content can be, for example, 30% by mass or more, 40% by mass or more, 50% by mass or more, 60% by mass or more, 65% by mass or more, 70% by mass or more, 75% by mass or more, or 80% by mass or more, based on the mass of the adenosine-containing composition. The water content can be, for example, 95% by mass or less, 90% by mass or less, 85% by mass or less, or 80% by mass or less, based on the mass of the adenosine-containing composition.
[0051] [(D) Polyhydric alcohol] The adenosine-containing composition of the present disclosure may further contain a polyhydric alcohol. The following compounds may be used as the polyhydric alcohol. Among these, propylene glycol, dipropylene glycol, 1,3-butylene glycol, etc. are preferred in the adenosine-containing composition of the present disclosure. Addition of these polyhydric alcohols can enhance the solubility of adenosine and the effect of inhibiting precipitation.
[0052] The content of the polyhydric alcohol can be, for example, 5% by mass or more, 10% by mass or more, 15% by mass or more, 20% by mass or more, 25% by mass or more, 30% by mass or more, or 40% by mass or more, based on the mass of the adenosine-containing composition. The content of the polyhydric alcohol can be, for example, 50% by mass or less, 40% by mass or less, 35% by mass or less, 30% by mass or less, 25% by mass or less, or 20% by mass or less, based on the mass of the adenosine-containing composition.
[0053] Examples of polyhydric alcohols include dihydric alcohols (e.g., ethylene glycol, propylene glycol, trimethylene glycol, 1,2-butylene glycol, 1,3-butylene glycol, tetramethylene glycol, 2,3-butylene glycol, pentamethylene glycol, 2-butene-1,4-diol, hexylene glycol, octylene glycol, etc.); trihydric alcohols (e.g., glycerin, trimethylolpropane, etc.); tetrahydric alcohols (e.g., pentaerythritol such as 1,2,6-hexanetriol, etc.); pentahydric alcohols (e.g., xylitol, etc.); hexahydric alcohols (e.g., sorbitol, mannitol, etc.); polyhydric alcohol polymers (e.g., diethylene glycol, dipropylene glycol, triethylene glycol, glycol, polypropylene glycol, tetraethylene glycol, diglycerin, polyethylene glycol, triglycerin, tetraglycerin, polyglycerin, etc.); dihydric alcohol alkyl ethers (e.g., ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol monobutyl ether, ethylene glycol monophenyl ether, ethylene glycol monohexyl ether, ethylene glycol mono-2-methylhexyl ether, ethylene glycol isoamyl ether, ethylene glycol benzyl ether, ethylene glycol isopropyl ether, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, ethylene glycol dibutyl ether, etc.);Dihydric alcohol alkyl ethers (e.g., diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol dimethyl ether, diethylene glycol diethyl ether, diethylene glycol butyl ether, diethylene glycol methyl ethyl ether, triethylene glycol monomethyl ether, triethylene glycol monoethyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, propylene glycol monobutyl ether, propylene glycol isopropyl ether, dipropylene glycol methyl ether, dipropylene glycol ethyl ether, dipropylene glycol butyl ether, etc.); dihydric alcohol ether esters (e.g., ethylene glycol monomethyl ether acetate, ethylene glycol monoethyl ether acetate, ethylene glycol monobutyl ether acetate, ethylene glycol monophenyl ether acetate, ethylene glycol diadipate, ethylene glycol disuccinate, diethylene glycol monoethyl ether acetate, diethylene glycol monobutyl ether acetate, propylene glycol monomethyl ether acetate, propylene glycol monoethyl ether acetate, propylene glycol monopropyl ether acetate, propylene glycol monophenyl ether acetate, etc.; glycerin monoalkyl ether (e.g., chimyl alcohol, selachyl alcohol, batyl alcohol, etc.); sugar alcohol (e.g., sorbitol, maltitol, maltotriose, mannitol, sucrose, erythritol, glucose, fructose, starch decomposition sugar, maltose, xylitol, starch decomposition sugar reduced alcohol, etc.); glycolide; tetrahydrofurfuryl alcohol; POE-tetrahydrofurfuryl alcohol; POP-butyl ether; POP·POE-butyl ether; tripolyoxypropylene glycerin ether; POP-glycerin ether; POP-glycerin ether phosphate; POP·POE-pentane erythritol ether, polyglycerin, etc.;
[0054] [ethanol] In the adenosine-containing composition of the present disclosure, the ethanol content is less than 20% by mass, preferably 15% by mass or less, more preferably 10% by mass or less, more preferably 5% by mass or less, and even more preferably substantially absent (0% by mass) in the adenosine-containing composition. By reducing the ethanol content, skin irritation can be reduced. In addition, the adenosine-containing composition can be applied to people who are hypersensitive to ethanol and / or have an allergic reaction. [(E)Other] The adenosine-containing composition of the present disclosure may contain other ingredients, such as water-soluble alcohols, oily ingredients, powders, anionic surfactants, cationic surfactants, amphoteric surfactants, hydrophilic nonionic surfactants, lipophilic nonionic surfactants, thickeners, moisturizers, film-forming agents, oil-soluble UV absorbers, water-soluble UV absorbers, sequestering agents, amino acids, organic amines, polymer emulsions, pH adjusters, skin nutrients, vitamins, antioxidants, antioxidant aids, fragrances, and the like, as needed, within the scope that does not inhibit the effects of the present disclosure.
[0055] Examples of the water-soluble alcohol include at least one selected from lower alcohols, polyhydric alcohols, polyhydric alcohol polymers, dihydric alcohol alkyl ethers, dihydric alcohol alkyl ethers, dihydric alcohol ether esters, glycerin monoalkyl ethers, sugar alcohols, monosaccharides, oligosaccharides, polysaccharides, and derivatives thereof.
[0056] Examples of the lower alcohol include propanol, isopropanol, isobutyl alcohol, and t-butyl alcohol.
[0057] Examples of monosaccharides include trioses (e.g., D-glyceryl aldehyde, dihydroxyacetone, etc.), tetraoses (e.g., D-erythrose, D-erythrulose, D-threose, erythritol, etc.), pentoses (e.g., L-arabinose, D-xylose, L-lyxose, D-arabinose, D-ribose, D-ribulose, D-xylulose, L-xylulose, etc.), hexoses (e.g., D-glucose, D-talose, D-psychose, D-galactose, D-fructose, L-galactose, L-mannose, D- Examples of the sugar include at least one selected from the group consisting of sugars such as tagatose, seven-carbon sugars (e.g., aldoheptose, heptulose, etc.), eight-carbon sugars (e.g., octulose, etc.), deoxy sugars (e.g., 2-deoxy-D-ribose, 6-deoxy-L-galactose, 6-deoxy-L-mannose, etc.), amino sugars (e.g., D-glucosamine, D-galactosamine, sialic acid, aminouronic acid, muramic acid, etc.), and uronic acids (e.g., D-glucuronic acid, D-mannuronic acid, L-guluronic acid, D-galacturonic acid, L-iduronic acid, etc.).
[0058] Examples of oligosaccharides include at least one selected from sucrose, gunthianose, umbelliferose, lactose, planteose, isolichinoses, α,α-trehalose, raffinose, lychinoses, umbilicin, stachyose, verbascoses, and the like.
[0059] Examples of polysaccharides include at least one selected from cellulose, quince seed, chondroitin sulfate, starch, galactan, dermatan sulfate, glycogen, gum arabic, heparan sulfate, hyaluronic acid, tragacanth gum, keratan sulfate, chondroitin, xanthan gum, mucoitin sulfate, guar gum, dextran, keratosulfate, locust bean gum, succinoglucan, and caronic acid.
[0060] Examples of the other polyols include at least one selected from polyoxyethylene methyl glucoside (Glucam E-10), polyoxypropylene methyl glucoside (Glucam P-10), and the like.
[0061] As the oily component, for example, liquid oils and fats, solid oils and fats, waxes, hydrocarbons, higher fatty acids, higher alcohols, synthetic ester oils, silicone oils, and the like can be used.
[0062] Examples of liquid oils and fats include avocado oil, camellia oil, turtle oil, macadamia nut oil, corn oil, mink oil, olive oil, rapeseed oil, egg yolk oil, sesame oil, persic oil, wheat germ oil, sasanqua oil, castor oil, linseed oil, safflower oil, cottonseed oil, perilla oil, soybean oil, peanut oil, tea seed oil, kaya oil, rice bran oil, Chinese tung oil, Japanese tung oil, jojoba oil, germ oil, and triglycerin.
[0063] Examples of solid fats and oils include cacao butter, coconut oil, horse tallow, hardened coconut oil, palm oil, beef tallow, mutton tallow, hardened beef tallow, palm kernel oil, lard, beef bone fat, Japan Rice Kernel Oil, hardened oil, beef foot fat, Japan Rice, and hardened castor oil.
[0064] Examples of waxes include beeswax, candelilla wax, cotton wax, carnauba wax, bayberry wax, ivory wax, whale wax, montan wax, bran wax, lanolin, kapok wax, lanolin acetate, liquid lanolin, sugarcane wax, lanolin fatty acid isopropyl, hexyl laurate, reduced lanolin, jojoba wax, hard lanolin, shellac wax, POE lanolin alcohol ether, POE lanolin alcohol acetate, POE cholesterol ether, lanolin fatty acid polyethylene glycol, and POE hydrogenated lanolin alcohol ether.
[0065] Examples of the hydrocarbon oil include liquid paraffin, ozokerite, squalane, pristane, paraffin, ceresin, squalene, petrolatum, and microcrystalline wax.
[0066] Examples of higher alcohols that can be used include straight-chain alcohols (e.g., lauryl alcohol, cetyl alcohol, stearyl alcohol, behenyl alcohol, myristyl alcohol, oleyl alcohol, cetostearyl alcohol, etc.); branched-chain alcohols (e.g., monostearyl glycerin ether (batyl alcohol), 2-decyltetradecinol, lanolin alcohol, cholesterol, phytosterol, hexyldodecanol, isostearyl alcohol, octyldodecanol, etc.); and the like.
[0067] Synthetic ester oils include isopropyl myristate, cetyl octanoate, octyldodecyl myristate, isopropyl palmitate, butyl stearate, hexyl laurate, myristyl myristate, decyl oleate, hexyldecyl dimethyloctanoate, cetyl lactate, myristyl lactate, lanolin acetate, isocetyl stearate, isocetyl isostearate, cholesteryl 12-hydroxystearate, ethylene glycol di-2-ethylhexanoate, dipentaerythritol fatty acid ester, N-alkyl glycol monoisostearate, neopentyl glycol dicaprate, diisostearyl malate, glycerin di-2-heptylundecanoate, trimethylolpropane tri-2-ethylhexanoate, trimethylolpropane triisostearate, pentaerythritol tetra-2-ethylhexanoate, ... -Glyceryl ethylhexanoate, triethylhexanoin, glyceryl trioctanoate, glyceryl triisopalmitate, trimethylolpropane triisostearate, cetyl 2-ethylhexanoate, 2-ethylhexyl palmitate, glyceryl trimyristate, tri-2-heptylundecanoate glyceride, castor oil fatty acid methyl ester, oleyl oleate, acetoglyceride, palmitic acid 2- Examples of the glycerin-based fatty acid esters include heptylundecyl, diisobutyl adipate, N-lauroyl-L-glutamic acid-2-octyldodecyl ester, di-2-heptylundecyl adipate, ethyl laurate, di-2-ethylhexyl sebacate, 2-hexyldecyl myristate, 2-hexyldecyl palmitate, 2-hexyldecyl adipate, diisopropyl sebacate, 2-ethylhexyl succinate, and triethyl citrate.
[0068] Examples of silicone oils include silicone compounds such as dimethylpolysiloxane, methylhydrogenpolysiloxane, methylphenylpolysiloxane, stearoxymethylpolysiloxane, polyether-modified organopolysiloxane, fluoroalkyl-polyoxyalkylene-co-modified organopolysiloxane, alkyl-modified organopolysiloxane, terminal-modified organopolysiloxane, fluorine-modified organopolysiloxane, amino-modified organopolysiloxane, silicone gel, acrylic silicone, trimethylsiloxysilicate, and silicone RTV rubber.
[0069] Examples of powders include inorganic powders (e.g., talc, kaolin, mica, sericite, white mica, gold mica, synthetic mica, red mica, black mica, lithia mica, calcined mica, calcined talc, vermiculite, magnesium carbonate, calcium carbonate, aluminum silicate, barium silicate, calcium silicate, magnesium silicate, strontium silicate, tungstate metal salts, magnesium, silica, zeolite, glass, barium sulfate, calcined calcium sulfate (calcined gypsum), calcium phosphate, fluorapatite, hydroxyapatite, ceramic powder, metal soap (e.g., zinc myristate, calcium palmitate, aluminum stearate), boron nitride, etc.); organic powders (e.g., polyamide resin powder (nylon powder), polyethylene powder, polymethylmethacrylate powder, polystyrene powder, styrene and acrylic acid copolymer resin powder, benzoguanamine resin powder, polytetrafluoroethylene powder, cellulose powder, silicone resin powder, silk powder, wool powder, urethane powder, etc.; inorganic white pigments (e.g., titanium dioxide, zinc oxide, etc.); inorganic red pigments (e.g., iron oxide (red oxide), iron titanate, etc.); inorganic brown pigments (γ-iron oxide, etc.), inorganic yellow pigments (yellow iron oxide, ocher, etc.), inorganic black pigments (black iron oxide, carbon black, low-order titanium oxide, etc.), inorganic purple pigments (e.g., manganese violet, cobalt violet, etc.); inorganic green pigments (e.g., chromium oxide, chromium hydroxide, cobalt titanate, etc.); inorganic blue pigments (e.g., ultramarine, Prussian blue, etc.); pearl pigments (e.g., titanium oxide coated mica, titanium oxide coated bismuth oxychloride, titanium oxide coated talc, colored titanium oxide coated mica, bismuth oxychloride, fish scale foil, etc.); metal powder pigments (e.g., aluminum powder, copper powder, etc.);Organic pigments such as zirconium, barium or aluminum lakes (e.g., organic pigments such as Red 201, Red 202, Red 204, Red 205, Red 220, Red 226, Red 228, Red 405, Orange 203, Orange 204, Yellow 205, Yellow 401, and Blue 404, Red 3, Red 104, Red 106, Red 227, Red 230, Red 401, Red 505, Orange 205, Yellow 4, Yellow 5, Yellow 202, Yellow 203, Green 3 and Blue 1, etc.); natural pigments (e.g., chlorophyll, β-carotene, etc.); wax powders (e.g., carnauba wax powder, etc.); starch powders (e.g., corn starch powder, rice starch powder, etc.), etc. may be used.
[0070] When there are components (except adenosine) that are not soluble in aqueous solvents, such as precipitation-inhibiting components and fragrances, a surfactant can be added to dissolve such components. The surfactant may be added in an amount necessary for the components that are insoluble in aqueous solvents to dissolve in the solvent. In order to reduce irritation to the skin and to suppress stickiness upon application, it is preferable that the surfactant content is low. For example, it is preferable that the surfactant content is 1% by mass or less relative to the mass of the adenosine-containing composition.
[0071] Examples of anionic surfactants include fatty acid soaps (e.g., sodium laurate, sodium palmitate, etc.); higher alkyl sulfates (e.g., sodium lauryl sulfate, potassium lauryl sulfate, etc.); alkyl ether sulfates (e.g., POE-lauryl triethanolamine sulfate, sodium POE-lauryl sulfate, etc.); N-acylsarcosinates (e.g., sodium lauroyl sarcosinate, etc.); higher fatty acid amide sulfonates (e.g., sodium N-stearoyl-N-methyl taurine, sodium N-myristoyl-N-methyl taurine, sodium coconut oil fatty acid methyl taurine, sodium lauryl methyl tauride, etc.); phosphates (sodium POE-oleyl ether phosphate, sodium POE-stearyl ether phosphate, etc.); sulfosuccinates (e.g., sodium di-2-ethylhexyl sulfosuccinate, sodium monolauroyl monoethanolamide polyoxyethylene sulfosuccinate, sodium lauryl polypropylene sulfonate ... Sodium glycol sulfosuccinate, etc.); alkylbenzene sulfonates (e.g., sodium linear dodecylbenzene sulfonate, triethanolamine linear dodecylbenzene sulfonate, linear dodecylbenzene sulfonic acid, etc.); higher fatty acid ester sulfates (e.g., sodium hydrogenated coconut oil fatty acid glycerin sulfate, etc.); N-acyl glutamates (e.g., monosodium N-lauroyl glutamate, disodium N-stearoyl glutamate, monosodium N-myristoyl-L-glutamate, etc.); sulfated oils (e.g., turmeric oil, etc.); POE-alkyl ether carboxylic acids; POE-alkyl allyl ether carboxylates; α-olefin sulfonates; higher fatty acid ester sulfonates; secondary alcohol sulfates; higher fatty acid alkylolamide sulfates; sodium lauroyl monoethanolamide succinate; ditriethanolamine N-palmitoyl aspartate; sodium caseinate, etc. can be used.
[0072] Examples of cationic surfactants include alkyltrimethylammonium salts (e.g., stearyltrimethylammonium chloride, lauryltrimethylammonium chloride, etc.); alkylpyridinium salts (e.g., cetylpyridinium chloride, etc.); dialkyldimethylammonium salts (e.g., distearyldimethylammonium chloride); poly(N,N'-dimethyl-3,5-methylenepiperidinium chloride); alkyl quaternary ammonium salts; alkyldimethylbenzylammonium salts; alkylisoquinolinium salts; dialkylmorphonium salts; POE-alkylamines; alkylamine salts; polyamine fatty acid derivatives; amyl alcohol fatty acid derivatives; benzalkonium chloride; benzethonium chloride, etc.
[0073] Examples of amphoteric surfactants include imidazoline-based amphoteric surfactants (e.g., 2-undecyl-N,N,N-(hydroxyethylcarboxymethyl)-2-imidazoline sodium, 2-cocoyl-2-imidazolinium hydroxide-1-carboxyethyloxy disodium salt, etc.); betaine-based surfactants (e.g., 2-heptadecyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine, lauryl dimethylaminoacetic acid betaine, alkyl betaine, amido betaine, sulfobetaine, etc.).
[0074] Examples of hydrophilic nonionic surfactants include POE-sorbitan fatty acid esters (e.g., POE-sorbitan monooleate, POE-sorbitan monostearate, POE-sorbitan monooleate, POE-sorbitan tetraoleate, etc.); POE-sorbitol fatty acid esters (e.g., POE-sorbitol monolaurate, POE-sorbitol monooleate, POE-sorbitol pentaoleate, POE-sorbitol monostearate, etc.); POE-glycerin fatty acid esters (e.g., POE-glycerin monostearate, POE-monooleates such as POE-glycerol monoisostearate, POE-glycerol triisostearate, etc.; POE-fatty acid esters (e.g., POE-distearate, POE-monodioleate, ethylene glycol distearate, etc.); POE-alkyl ethers (e.g., POE-lauryl ether, POE-oleyl ether, POE-stearyl ether, POE-behenyl ether, POE-2-octyldodecyl ether, POE-cholestanol ether, etc.); Pluronic types (e.g., Pluronic etc.); POE·POP-alkyl ethers (e.g., POE·POP-cetyl ether, POE·POP-2-decyltetradecyl ether, POE·POP-monobutyl ether, POE·POP-hydrogenated lanolin, POE·POP-glycerin ether, etc.); tetraPOE·tetraPOP-ethylenediamine condensates (e.g., Tetronic, etc.); POE-castor oil hydrogenated castor oil derivatives (e.g., POE-castor oil, POE-hydrogenated castor oil, POE-hydrogenated castor oil monoisostearate, POE-hydrogenated castor oil triisostearate, POE -hydrogenated castor oil monopyroglutamic acid monoisostearate diester, POE-hydrogenated castor oil maleic acid, etc.); POE-beeswax and lanolin derivatives (e.g., POE-sorbitol beeswax, etc.); alkanolamides (e.g., coconut oil fatty acid diethanolamide, lauric acid monoethanolamide, fatty acid isopropanolamide, etc.); POE-propylene glycol fatty acid esters; POE-alkylamines; POE-fatty acid amides; sucrose fatty acid esters; alkylethoxydimethylamine oxide; trioleyl phosphate, etc.
[0075] Examples of lipophilic nonionic surfactants include sorbitan fatty acid esters (e.g., sorbitan monooleate, sorbitan monoisostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan sesquioleate, sorbitan trioleate, diglycerol sorbitan penta-2-ethylhexyl acid, diglycerol sorbitan tetra-2-ethylhexyl acid, etc.); glycerin polyglycerin fatty acids (e.g., glycerin monocottonseed oil fatty acid, glycerin monoerucate, glycerin sesquioleate, glycerin monostearate, α,α'-oleic acid pyroglutamic acid, glycerin monostearate malic acid, etc.); propylene glycol fatty acid esters (e.g., propylene glycol monostearate, etc.); hydrogenated castor oil derivatives; and glycerin alkyl ethers.
[0076] Examples of natural water-soluble polymers include plant-based polymers (e.g., gum arabic, tragacanth gum, galactan, guar gum, carob gum, karaya gum, carrageenan, pectin, agar, quince seed, algae colloids (cassou extract), starch (rice, corn, potato, wheat), glycyrrhizic acid); microbial polymers (e.g., xanthan gum, dextran, succinoglucan, pullulan, etc.); animal-based polymers (e.g., collagen, casein, albumin, gelatin, etc.), etc.
[0077] Examples of semi-synthetic water-soluble polymers include starch-based polymers (e.g., carboxymethyl starch, methylhydroxypropyl starch, etc.); cellulose-based polymers (methyl cellulose, ethyl cellulose, methylhydroxypropyl cellulose, hydroxyethyl cellulose, sodium cellulose sulfate, hydroxypropyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, crystalline cellulose, cellulose powder, etc.); alginic acid-based polymers (e.g., sodium alginate, propylene glycol alginate, etc.).
[0078] Examples of thickening agents include gum arabic, carrageenan, karaya gum, tragacanth gum, carob gum, quince seed, casein, dextrin, gelatin, sodium pectinate, sodium alginate, methylcellulose, ethylcellulose, carboxymethylcellulose (CMC), hydroxyethylcellulose, hydroxypropylcellulose, polyvinyl alcohol (PVA), polyvinyl methyl ether (PVM), PVP (polyvinylpyrrolidone), sodium polyacrylate, carboxyvinyl polymer, locust bean gum, guar gum, tamarind gum, dialkyldimethylammonium cellulose sulfate, xanthan gum, magnesium aluminum silicate, bentonite, hectorite, magnesium aluminum silicate (veegum), laponite, silicic anhydride, taurate-based synthetic polymers, and acrylate-based synthetic polymers.
[0079] Examples of moisturizing agents include polyethylene glycol, propylene glycol, glycerin, 1,3-butylene glycol, xylitol, sorbitol, maltitol, chondroitin sulfate, hyaluronic acid, mucoitin sulfate, caronic acid, atelocollagen, cholesteryl-12-hydroxystearate, sodium lactate, bile salts, dl-pyrrolidone carboxylates, alkylene oxide derivatives, short-chain soluble collagen, diglycerin (EO)PO adducts, Rosa rugosa extract, Achillea millefolium extract, and Melilot extract.
[0080] Examples of coating agents include anionic coating agents (e.g., (meth)acrylic acid / (meth)acrylic acid ester copolymers, methyl vinyl ether / maleic anhydride high polymers, etc.), cationic coating agents (e.g., cationized cellulose, dimethyl diallyl ammonium chloride polymers, dimethyl diallyl ammonium chloride / acrylamide copolymers, etc.), and nonionic coating agents (e.g., polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl acetate, polyacrylic acid ester copolymers, (meth)acrylamide, polymeric silicone, silicone resins, trimethylsiloxysilicate, etc.).
[0081] Examples of oil-soluble ultraviolet absorbers include benzoic acid-based ultraviolet absorbers (e.g., para-aminobenzoic acid (hereinafter, abbreviated as PABA), PABA monoglycerin ester, N,N-dipropoxy PABA ethyl ester, N,N-diethoxy PABA ethyl ester, N,N-dimethyl PABA ethyl ester, N,N-dimethyl PABA butyl ester, N,N-dimethyl PABA ethyl ester, diethylaminohydroxybenzoylhexyl benzoate, etc.); anthranilic acid-based ultraviolet absorbers Absorbers (e.g., homomenthyl-N-acetylanthranilate, etc.); salicylic acid-based ultraviolet absorbers (e.g., ethylhexyl salicylate, amyl salicylate, menthyl salicylate, homomenthyl salicylate, octyl salicylate, phenyl salicylate, benzyl salicylate, p-isopropanol phenyl salicylate, homosalate, etc.); cinnamic acid-based ultraviolet absorbers (e.g., octyl methoxycinnamate, ethyl-4-isopropyl cinnamate, methyl-2,5 -Diisopropyl cinnamate, ethyl 2,4-diisopropyl cinnamate, methyl 2,4-diisopropyl cinnamate, propyl p-methoxycinnamate, isopropyl p-methoxycinnamate, isoamyl p-methoxycinnamate, octyl p-methoxycinnamate (2-ethylhexyl p-methoxycinnamate, ethylhexyl methoxycinnamate), 2-ethoxyethyl p-methoxycinnamate, cyclohexyl p-methoxycinnamate mate, ethyl-α-cyano-β-phenylcinnamate, 2-ethylhexyl-α-cyano-β-phenylcinnamate, glyceryl mono-2-ethylhexanoyl-di-paramethoxycinnamate, etc.;3-(4'-methylbenzylidene)-d,l-camphor, 3-benzylidene-d,l-camphor;2-phenyl-5-methylbenzoxazole;2,2'-hydroxy-5-methylphenylbenzotriazole;2-(2'-hydroxy-5'-t-octylphenyl) benzotriazole;2-(2'-hydroxy-5'-methylphenylbenzotriazole;dibenzalazine;dianisoylmethane;4-methoxy-4'-t-butyldibenzoylmethane;5-(3,3-dimethyl-2-norbornylidene)-3-pentan-2-one, dimorpholinopyridazinone;2-Ethylhexyl-2-cyano-3,3-diphenylacrylate (Octocrellin); 2,4-bis-{[4-(2-ethylhexyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-(1,3,5)-triazine, benzophenone-based UV absorbers (e.g., 2,4-dihydroxybenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone, 2,2'-dihydroxy-4,4'-dimethoxybenzophenone, 2,2',4 , 4'-tetrahydroxybenzophenone, 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2-hydroxy-4-methoxybenzophenone-5-sulfonate, 4-phenylbenzophenone, 2-ethylhexyl-4'-phenyl-benzophenone-2-carboxylate, 2-hydroxy-4-n-octoxybenzophenone, 4-hydroxy-3-carboxybenzophenone, etc.;
[0082] Examples of water-soluble ultraviolet absorbers include benzophenone-based ultraviolet absorbers (e.g., 2-hydroxy-4-methoxybenzophenone-5-sulfonate, etc.), benzylidene camphor-based ultraviolet absorbers (benzylidene camphorsulfonic acid, terephthalidenedichamnorsulfonic acid, etc.), and phenylbenzimidazole-based ultraviolet absorbers (phenylbenzimidazole sulfonic acid, etc.).
[0083] Examples of sequestering agents include 1-hydroxyethane-1,1-diphosphonic acid, 1-hydroxyethane-1,1-diphosphonic acid tetrasodium salt, disodium edetate, trisodium edetate, tetrasodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, gluconic acid, phosphoric acid, citric acid, ascorbic acid, succinic acid, edetic acid, and trisodium ethylenediaminehydroxyethyltriacetate.
[0084] Examples of the amino acid include neutral amino acids (e.g., threonine, cysteine, etc.), basic amino acids (e.g., hydroxylysine, etc.), etc. Examples of the amino acid derivatives include sodium acyl sarcosine (sodium lauroyl sarcosine), acyl glutamate, sodium acyl β-alanine, glutathione, pyrrolidone carboxylic acid, etc.
[0085] Examples of the organic amine include monoethanolamine, diethanolamine, triethanolamine, morpholine, triisopropanolamine, 2-amino-2-methyl-1,3-propanediol, and 2-amino-2-methyl-1-propanol.
[0086] Examples of polymer emulsions include acrylic resin emulsions, polyethyl acrylate emulsions, acrylic resin liquids, polyacrylic alkyl ester emulsions, polyvinyl acetate resin emulsions, and natural rubber latex.
[0087] Examples of pH adjusters include buffers such as lactic acid-sodium lactate, citric acid-sodium citrate, and succinic acid-sodium succinate.
[0088] Examples of vitamins include vitamins A, B1, B2, B6, C, E and their derivatives, pantothenic acid and its derivatives, biotin, etc.
[0089] Examples of the antioxidant include tocopherols, dibutylhydroxytoluene, butylhydroxyanisole, and gallic acid esters.
[0090] Examples of the antioxidant aid include phosphoric acid, citric acid, ascorbic acid, maleic acid, malonic acid, succinic acid, fumaric acid, cephalin, hexametaphosphate, phytic acid, and ethylenediaminetetraacetic acid.
[0091] Other possible ingredients include, for example, preservatives (ethylparaben, butylparaben, chlorphenesin, phenoxyethanol, etc.); anti-inflammatory agents (for example, glycyrrhizic acid derivatives, glycyrrhetinic acid derivatives, salicylic acid derivatives, hinokitiol, zinc oxide, allantoin, etc.); whitening agents (for example, placenta extract, saxifrage extract, arbutin, etc.); various extracts (for example, Phellodendron bark, Coptis japonica, Lithospermum root, Peony root, Swertia japonica, Birch, Sage, Loquat, Carrot, Aloe, Mallow, Iris, Grape, Coix seed, Loofah, Lily, Saffron, Cnidium rhizome, Ginger, Hypericum perforatum, Ononis, Garlic, Capsicum annuum, Citrus aurantium, Tomentosum, float, seaweed, etc.), activators (for example, royal jelly, photosensitizers, cholesterol derivatives, etc.); blood circulation promoters (for example, vanillylamide nonylate, nicotinic acid benzyl ester, nicotinic acid β-butoxyethyl ester, capsaicin, zingerone, cantharides tincture, ichthammol, tannic acid, α-borneol, tocopherol nicotinate, inositol hexanicotinate, cyclandelate, cinnarizine, tolazoline, acetylcholine, verapamil, cepharanthine, γ-oryzanol, etc.); antiseborrheic agents (for example, sulfur, thianthol, etc.); anti-inflammatory agents (for example, tranexamic acid, thiotaurine, hypotaurine, etc.), etc.
[0092] Furthermore, the compositions of the present disclosure may also appropriately contain caffeine, tannin, verapamil, tranexamic acid and derivatives thereof, various herbal extracts such as licorice, quince, and Japanese anemone, drugs such as tocopherol acetate, glycyrrhizic acid, glycyrrhizic acid and derivatives thereof or salts thereof, skin whitening agents such as vitamin C, magnesium ascorbyl phosphate, ascorbyl glucoside, arbutin, and kojic acid, and amino acids and derivatives thereof such as arginine and lysine.
[0093] In the adenosine-containing composition of the present disclosure, precipitation of adenosine is suppressed. For example, even if the temperature is shifted from 25° C. or higher to a low-temperature environment, precipitation of adenosine dissolved in a solvent is suppressed. Even if adenosine precipitates in a low-temperature environment, adenosine can be naturally dissolved by placing the adenosine-containing composition in an environment of 25° C. or higher again. This makes it possible to make a composition in which adenosine can be easily applied to the skin. In addition, a process such as heating to redissolve precipitated adenosine is not required (changes in environmental temperature are not included in the term "heating").
[0094] In the adenosine-containing composition of the present disclosure, ethanol is not required to promote dissolution of adenosine. Therefore, the content of ethanol can be reduced or ethanol can be eliminated. This allows the adenosine-containing composition to be applied to people whose skin is sensitive to ethanol or who are allergic to ethanol.
[0095] The adenosine-containing composition of the present disclosure can be applied to skin external preparations, particularly skin external preparations applied to the scalp. The adenosine-containing composition of the present disclosure can be applied to, for example, hair growth agents, hair care agents, hair thickening agents, hair growth agents, hair loss prevention agents, shampoos, rinses, conditioners, etc.
[0096] The method for producing the adenosine-containing composition of the present disclosure will be described. For example, a precipitation-inhibiting component is dissolved in an aqueous solvent containing water. Next, adenosine is added to the aqueous solvent and dissolved. This makes it possible to prepare the adenosine-containing composition of the present disclosure. As long as each component can be dissolved, the order of addition may be any. Adenosine is preferably dissolved in an aqueous solvent at 25°C or higher.
[0097] There are cases where it is difficult or simply impractical to directly identify the adenosine-containing compositions of the present disclosure by their composition, structure, etc. In such cases, it should be permitted to identify the adenosine-containing compositions of the present disclosure by their method of manufacture.
[0098] A method for inhibiting precipitation of adenosine according to a second embodiment of the present disclosure will be described. The method includes a dissolving step of dissolving adenosine and a first component in an aqueous solvent. The first component is at least one selected from the group consisting of caffeine, glycyrrhizic acid and its salts, salicylic acid and its salts, and plant extracts. The first component corresponds to the precipitation inhibiting component in the first embodiment. The order of addition of each component may be any order.
[0099] In the dissolving step, adenosine is preferably dissolved in an aqueous solvent at 25° C. or higher.
[0100] The method for suppressing precipitation of adenosine can further include, in the dissolving step, a step of adding a second component, such as a surfactant, that solubilizes the first component in the aqueous solvent if the first component is not soluble in the aqueous solvent.
[0101] The method for suppressing precipitation of adenosine may further include a step of placing (storing) the composition prepared in the dissolving step in an environment at room temperature of 25° C. or higher. This makes it possible to suppress precipitation of adenosine. Even if adenosine precipitates due to a decrease in solubility caused by low temperature, the natural dissolution of adenosine can be promoted.
[0102] The amount of adenosine added can be the same as in the first embodiment. The description of the amount of adenosine added in the first embodiment is incorporated herein, and the description will be omitted here. Adenosine is preferably dissolved in an aqueous solvent at 25° C. or higher.
[0103] The type and amount of the precipitation-inhibiting component may be the same as in the first embodiment. The type and amount of the precipitation-inhibiting component are the same as in the first embodiment, and the description thereof is omitted here.
[0104] The aqueous solvent contains water. The amount of water may be 60% by mass or more based on the mass of the aqueous solvent. The amount of water added may be the same as that of the first embodiment. The description of the first embodiment is used for the amount of water added, and the description here is omitted.
[0105] The amount of ethanol is less than 20% by mass, preferably 15% by mass or less, more preferably 10% by mass or less, and even more preferably 5% by mass or less, relative to the total mass of the aqueous solvent or each component, and is even more preferably substantially absent (0% by mass).
[0106] The method for suppressing precipitation of adenosine may further include a step of adding a polyhydric alcohol to the aqueous solvent and / or to the composition prepared in the dissolving step. The type and amount of the polyhydric alcohol may be the same as those in the first embodiment. The description of the first embodiment is used to refer to the type and amount of the polyhydric alcohol, and the description here is omitted.
[0107] According to the method for suppressing the precipitation of adenosine, the precipitation of adenosine dissolved in an aqueous solvent can be suppressed even with a minimum amount of ethanol used. In particular, the precipitation of adenosine in a low-temperature environment can be suppressed. Even if adenosine precipitates in a low-temperature environment, the precipitate can be naturally dissolved by returning the environment to 25°C or higher, and the dissolved state of adenosine at room temperature can be maintained. Furthermore, a treatment such as heating to re-dissolve precipitated adenosine is not required. EXAMPLES
[0108] The adenosine-containing composition and the method for inhibiting adenosine precipitation of the present disclosure will be described below with reference to examples. However, the adenosine-containing composition and the method for inhibiting adenosine precipitation of the present disclosure are not limited to the following examples. The unit of the content of each component shown in each table is mass%.
[0109] [Test Examples 1-81] The adenosine-containing composition was prepared at 25°C. The adenosine-containing composition immediately after preparation was a one-phase aqueous composition, and adenosine and the precipitation-inhibiting component were dissolved in the composition. The prepared adenosine-containing composition was left at rest in an environment of 0°C for 4 weeks, and it was visually confirmed whether precipitation occurred in the composition. Next, the adenosine-containing composition that had been left at rest in an environment of 0°C for 4 weeks was left at rest in an environment of 25°C for 7 days, and it was visually confirmed whether precipitation remained in the composition (whether the precipitation redissolved). The test results were evaluated according to the following criteria. A commercially available plant extract was used.
[0110] A: No precipitation occurred even in an environment of 0°C; B: Precipitation occurred in an environment of 0°C, but when the composition was returned to an environment of 25°C, the precipitate redissolved naturally; C: Precipitates were formed in an environment at 0° C., and even when the composition was returned to an environment at 25° C., the precipitates remained.
[0111] [Test Examples 1-36] A precipitation test was carried out by changing the type of precipitation-inhibiting component (B) using the composition shown in Table 1 as the basic composition. Table 2 shows the precipitation-inhibiting components tested and their contents (X mass %), as well as the test results.
[0112] In Test Example 36, which did not contain ethanol or a precipitation-inhibiting component, adenosine precipitated at 0° C. did not redissolve even when returned to 25° C. On the other hand, in Test Examples 1 to 35, in which a precipitation-inhibiting component was added, adenosine did not precipitate even at 0° C., or, even if it precipitated, it naturally redissolved when returned to 25° C. This suggests that the precipitation-inhibiting component has the effect of inhibiting the precipitation of adenosine or facilitating the resolubilization of precipitated adenosine (or the effect of precipitating adenosine that is easily redissolved).
[0113] [Table 1]
[0114] [Table 2]
[0115] [Test Examples 37-72] Using some of the precipitation-inhibiting ingredients used in Test Examples 1 to 35, compositions with different contents of the precipitation-inhibiting ingredients and compositions combining multiple precipitation-inhibiting ingredients were prepared. In some of the Test Examples, the amount of adenosine was increased compared to Test Examples 1 to 36. When the precipitation-inhibiting ingredient and the fragrance did not dissolve in the solvent, a surfactant was added. All of the compositions in Test Examples 37 to 72 were one-phase aqueous compositions immediately after preparation, and the adenosine and precipitation-inhibiting ingredient were dissolved in the solvent. Tables 3 to 8 show the compositions and test results.
[0116] The precipitation-inhibiting effect was confirmed in all of Test Examples 37 to 49, which were different from Test Examples 1 to 35 in that the content of the precipitation-inhibiting component was changed. -4 % by mass or more. Taking the results of Test Examples 1 to 35 into consideration, it was observed that the deposition-inhibiting effect tends to be higher when the deposition-inhibiting component is increased relative to adenosine.
[0117] The deposition-inhibiting effect was also confirmed in Test Examples 50 to 72, in which a plurality of deposition-inhibiting components were combined.
[0118] [Table 3]
[0119] [Table 4]
[0120] [Table 5]
[0121] [Table 6]
[0122] [Table 7]
[0123] [Table 8]
[0124] [Test Examples 73-81] In Test Examples 73 to 78, compositions containing ethanol but not containing a deposition-inhibiting component were prepared. However, after cooling, the compositions were left to stand at room temperature for 4 weeks to confirm the presence or absence of deposition. In Test Example 79, a composition containing a polyhydric alcohol but not containing ethanol and a deposition-inhibiting component was prepared. In Test Example 80, a composition containing a deposition-inhibiting component but not containing ethanol and a polyhydric alcohol was prepared. In Test Example 81, a composition containing a deposition-inhibiting component, ethanol, and a polyhydric alcohol was prepared. All of the compositions in Test Examples 73 to 81 were one-phase aqueous compositions immediately after preparation, and adenosine and a deposition-inhibiting component were dissolved in the solvent. Tables 9 to 10 show the compositions and test results.
[0125] In Test Examples 76 to 78, which had a high ethanol content, the adenosine precipitation-inhibiting effect was high. On the other hand, in Test Examples 73 to 75, which had a low ethanol content, the adenosine precipitation-inhibiting effect was not obtained. Therefore, in a composition that does not contain a precipitation-inhibiting component, it is considered that sufficient precipitation inhibition cannot be achieved when the ethanol content is less than 20 mass%.
[0126] Test Example 79, which contained only polyhydric alcohol, did not provide sufficient adenosine precipitation inhibition effect. Test Example 80 showed that the precipitation inhibition effect of the precipitation inhibition component could be obtained without ethanol and polyhydric alcohol. Test Example 81 showed that the precipitation inhibition effect of the precipitation inhibition component could be obtained even in the presence of ethanol.
[0127] [Table 9]
[0128] [Table 10]
[0129] The adenosine-containing composition and the method for inhibiting adenosine deposition of the present invention have been described based on the above-mentioned embodiments and examples, but are not limited to the above-mentioned embodiments and examples, and may include various modifications, changes, and improvements to each disclosed element (including elements described in the claims, specification, and drawings) within the scope of the present invention and based on the basic technical idea of the present invention. Furthermore, various combinations, substitutions, and selections of each disclosed element are possible within the scope of the claims of the present invention.
[0130] Further objects, objectives and modes (including modifications) of the present invention will become apparent from the entire disclosure of the present invention including the claims.
[0131] With respect to numerical ranges set forth herein, unless otherwise stated, any numerical value or range falling within that range should be construed as being specifically set forth herein.
[0132] A part or all of the above-described embodiments may be described as, but are not limited to, the following supplementary notes. Each supplementary note may be combined with each claim in the claims. [Appendix 1] (A) Adenosine, (B) at least one selected from the group consisting of caffeine, glycyrrhizic acid and its salts, salicylic acid and its salts, and plant extracts; (C) water; Including, 1. An adenosine-containing composition, wherein the ethanol is less than 20% by weight based on the weight of the adenosine-containing composition. [Appendix 2] The adenosine-containing composition according to Appendix 1, wherein the plant extract is at least one selected from the group consisting of Angelica keiskei leaf / stem extract, apricot juice, ginkgo leaf extract, Satsuma mandarin peel extract, Scutellaria root extract, Panax ginseng root extract, Rosa canina fruit extract, Ononis extract, licorice root extract, Phellodendron amplexicaule bark extract, Sophora flavonoides root extract, Cherry leaf extract, Hypericum perforatum flower / leaf / stem extract, Crataegus monogyna flower extract, Horse chestnut seed extract, Achillea millefolium extract, Rosa centifolia flower extract, Prunus yedoensis leaf extract, Camellia japonica seed extract, Camellia japonica flower extract, Tencha extract, Lotus germ extract, Myrtus officinalis leaf extract, Bupleurum falcatum root extract, Melilot extract, Centaurea cyanus flower extract, Lemon extract, Rosemary extract, Rosemary leaf extract, Wild thyme extract, and Sanguisorba officinalis extract. [Appendix 3] 3. The adenosine-containing composition according to claim 1, wherein the content of the component (A) is 0.1% by mass to 5% by mass based on the mass of the adenosine-containing composition. [Appendix 4] The content of the component (B) is 1×10 based on the mass of the adenosine-containing composition. -4 4. The adenosine-containing composition according to any one of claims 1 to 3, wherein the adenosine-containing composition is at least 5% by mass. [Appendix 5] 5. The adenosine-containing composition according to any one of claims 1 to 4, wherein the content of the component (C) is 60% by mass or more based on the mass of the adenosine-containing composition. [Appendix 6] 6. The adenosine-containing composition according to any one of claims 1 to 5, further comprising 5% by mass to 40% by mass of a polyhydric alcohol relative to the mass of the adenosine-containing composition. [Appendix 7] A one-phase liquid composition, 7. The adenosine-containing composition according to any one of claims 1 to 6, wherein the component (A) and the component (B) are dissolved in the adenosine-containing composition at atmospheric pressure and 25°C. [Appendix 8] 8. The adenosine-containing composition according to any one of claims 1 to 7, which is substantially free of ethanol. [Appendix 9] 9. The adenosine-containing composition according to any one of claims 1 to 8, which is used as an external preparation for skin to be applied to the skin. [Appendix 10] 10. The adenosine-containing composition according to any one of claims 1 to 9, which is an external skin preparation for application to the scalp. [Appendix 11] Dissolving adenosine and the first component in an aqueous solvent containing less than 20% by mass of ethanol; A method for inhibiting precipitation of adenosine, wherein the first component is at least one selected from the group consisting of caffeine, glycyrrhizinic acid and its salts, salicylic acid and its salts, and plant extracts. [Appendix 12] 12. The method according to claim 11, wherein the aqueous solvent contains 60% or more by mass of water relative to the mass of the aqueous solvent. [Appendix 13] The method according to claim 11 or 12, wherein the plant extract is at least one selected from the group consisting of Angelica keiskei leaf / stem extract, apricot juice, ginkgo leaf extract, Satsuma mandarin peel extract, Scutellaria root extract, Panax ginseng root extract, Rosa canina fruit extract, Ononis extract, licorice root extract, Phellodendron amplexicaule bark extract, Sophora flavonoides root extract, Cherry leaf extract, Hypericum perforatum flower / leaf / stem extract, Crataegus monogyna flower extract, Horse chestnut seed extract, Achillea millefolium extract, Rosa centifolia flower extract, Prunus yedoensis leaf extract, Camellia japonica seed extract, Camellia japonica flower extract, Tencha extract, Lotus germ extract, Myrtus officinalis leaf extract, Bupleurum falcatum root extract, Melilot extract, Centaurea cyanus flower extract, Lemon extract, Rosemary extract, Rosemary leaf extract, Wild thyme extract, and Sanguisorba officinalis extract. [Appendix 14] The method according to any one of claims 1 to 13, wherein adenosine is added in an amount of 0.1% by mass to 5% by mass relative to the total mass of the composition. [Appendix 15] The first component is added in an amount of 1×10 -4 15. The method according to any one of claims 1 to 14, wherein the compound is added in an amount of at least 5% by mass. [Appendix 16] The method according to any one of claims 1 to 15, further comprising the step of adding to the aqueous solvent 5% by mass to 40% by mass of a polyhydric alcohol relative to the total mass of the composition. [Appendix 17] A method for using the adenosine-containing composition of the present disclosure, comprising using the adenosine-containing composition as an external skin preparation. [Appendix 18] A method of using the adenosine-containing composition of the present disclosure, comprising applying the adenosine-containing composition to the scalp. [Industrial Applicability]
[0133] The adenosine-containing composition and the method for inhibiting adenosine deposition of the present disclosure can be applied to skin external preparations, cleansers, etc. The adenosine-containing composition and the method for inhibiting adenosine deposition of the present disclosure can be applied to, for example, skin external preparations and cleansers applied to the scalp or hair. Examples of skin external preparations and cleansers include hair growth agents, hair nourishing agents, hair thickening agents, hair growth agents, hair loss prevention agents, shampoos, rinses, conditioners, etc.
Claims
1. (A) 0.2% to 2.5% by mass of adenosine; (B) 0.05% by mass to 1.5% by mass of at least one selected from the group consisting of glycyrrhizinic acid and salts thereof; (C) 60% by mass or more of water; Including, ethanol is less than 20% by weight based on the weight of the adenosine-containing composition; An adenosine-containing composition for use in an external skin preparation to be applied to the skin (excluding the scalp).
2. 10. The adenosine-containing composition of claim 1, which does not contain ethanol.
3. (A) 0.2% to 2.5% by mass of adenosine; (B) at least one selected from the group consisting of glycyrrhizinic acid and its salts, (C) 60% by mass or more of water; Including, Used in topical skin preparations applied to the skin (excluding the scalp), An adenosine-containing composition that does not contain ethanol.
4. The adenosine-containing composition according to any one of claims 1 to 3, wherein the content of component (A) is 0.2% by mass to 2% by mass based on the mass of the adenosine-containing composition.
5. 5. The adenosine-containing composition according to claim 3, wherein the content of the component (B) is 0.05% by mass to 1.5% by mass based on the mass of the adenosine-containing composition.
6. The adenosine-containing composition according to any one of claims 1 to 5, wherein the component (B) is dipotassium glycyrrhizinate or monoammonium glycyrrhizinate.
7. The adenosine-containing composition according to any one of claims 1 to 6, wherein the component (B) further comprises at least one selected from the group consisting of salicylic acid and its salts.
8. The adenosine-containing composition according to any one of claims 1 to 7, wherein the component (B) is a component that inhibits precipitation of the dissolved component (A).
9. The adenosine-containing composition according to any one of claims 1 to 8, further comprising 5% to 40% by weight of a polyhydric alcohol, based on the weight of the adenosine-containing composition.
10. A one-phase liquid composition, The adenosine-containing composition according to any one of claims 1 to 9, wherein the component (A) and the component (B) are dissolved in the adenosine-containing composition at atmospheric pressure and 25°C.
11. (A) 0.2% by mass to 2.5% by mass of adenosine; (B) 0.05% by mass to 1.5% by mass of at least one selected from the group consisting of glycyrrhizinic acid and its salts, and at least one selected from the group consisting of salicylic acid and its salts; (C) 60% by mass or more of water; Including, 1. An adenosine-containing composition, wherein the ethanol content is less than 20% by weight based on the weight of the adenosine-containing composition.
12. (A) 0.2% by mass to 2.5% by mass of adenosine; (B) at least one selected from the group consisting of glycyrrhizinic acid and its salts, and at least one selected from the group consisting of salicylic acid and its salts; (C) 60% by mass or more of water; Including, An adenosine-containing composition that does not contain ethanol.
13. The method includes a step of dissolving 0.2% by mass to 2.5% by mass of adenosine and a first component in an aqueous solvent containing 60% by mass or more of water and less than 20% by mass of ethanol, based on the total mass of the composition; A method for inhibiting precipitation of adenosine, wherein the first component is at least one selected from the group consisting of glycyrrhizinic acid and salts thereof, and at least one selected from the group consisting of salicylic acid and salts thereof.
14. 14. The method of claim 13, wherein the first component is dipotassium glycyrrhizinate or monoammonium glycyrrhizinate.
15. The method according to claim 13 or 14, used in a topical skin preparation to be applied to the skin (excluding the scalp).
16. The method according to any one of claims 13 to 15, wherein the first component is a component that inhibits precipitation of dissolved adenosine.
17. The method according to any one of claims 13 to 16, wherein the first component is added in an amount of 0.05% by mass or more relative to the total mass of the composition.
18. The method according to any one of claims 13 to 17, further comprising the step of adding 5% by mass to 40% by mass of a polyhydric alcohol to the aqueous solvent, based on the total mass of the composition.
Citation Information
Patent Citations
Percutaneous absorption promoter and skin care external preparation containing the same
JP2008179577A
Composition for external application
JP2008247752A
Aerosol agent
JP2009091341A
Cosmetic composition comprising at least one hydrotrope and at least one active compound
JP2015533170A
Hair cosmetics
JP2016102098A
